share_log

Adverum Biotechnologies Announces First Subject Dosed With Ixo-vec In Phase 2 LUNA Trial For Treatment Of Wet Age-Related Macular Degeneration

Benzinga Real-time News ·  Sep 14, 2022 08:08
Adverum Biotechnologies Announces First Subject Dosed With Ixo-vec In Phase 2 LUNA Trial For Treatment Of Wet Age-Related Macular Degeneration
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment